These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11348390)

  • 21. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmenopausal hormone replacement therapy: scientific review.
    Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
    JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).
    Wolmark N; Dunn BK
    Ann N Y Acad Sci; 2001 Dec; 949():99-108. PubMed ID: 11795386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen in postmenopausal women a safety perspective.
    Robinson E; Kimmick GG; Muss HB
    Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
    Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
    J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
    Pritchard KI
    Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular effects of aromatase inhibitors: data from clinical trials.
    Howell A; Cuzick J
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HRT opposed to low-dose tamoxifen (HOT study): rationale and design.
    Decensi A; Galli A; Veronesi U
    Recent Results Cancer Res; 2003; 163():104-11; discussion 264-6. PubMed ID: 12903847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.